Last reviewed · How we verify
NCT05517538
Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique
NA trial testing Electromyography-Needle Intramuscular Drug guidance in Glabellar Frown Lines in 15 participants. Completed in 15 December 2021.
2 December 2021
Quick facts
| Lead sponsor | Mohamed Hayder Oleish Salih |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 9 August 2021 |
| Primary completion | 2 December 2021 |
| Estimated completion | 15 December 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Electromyography-Needle Intramuscular Drug guidance
- Botulinum toxin type A (BOTULINUM TOXIN TYPE A) — full drug profile →
Conditions studied
- Glabellar Frown Lines — all drugs for Glabellar Frown Lines →
- Rhytides — all drugs for Rhytides →
- Wrinkle — all drugs for Wrinkle →
- Facial Expression — all drugs for Facial Expression →
Sponsor
Mohamed Hayder Oleish Salih
Who can join
Adults 25 to 60, any sex, with Glabellar Frown Lines or Rhytides. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to compare between the conventional palpation method of botulinum toxin type A injection and the electromyography-guided method using clinical parameters and electromyography analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05517538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05517538 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mohamed Hayder Oleish Salih
- Last refreshed: 26 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05517538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing